Prostate cancer (PCa) is the second most diagnosed cancer in men. In recent years, nuclear medicine has played an expanding role in diagnosing, staging, monitoring, and treating PCa. Specifically, the introduction of prostate-specific membrane antigen PET/computed tomography has significantly contributed to detecting locoregional and distant disease. Radioligand therapy, with its capacity to induce highly selective cytotoxic effects, is progressively being integrated into PCa therapy. The advent of novel therapeutic agents, additional indications, and a more comprehensive integration between nuclear imaging and therapy, represent the forefront of nuclear medicine in PCa.
The Urologic clinics of North America. 2024 Oct 10 [Epub]
Gregory Peters-Founshtein, Yael Eshet, Michal Sarfaty, Zohar Dotan, Onofrio Antonio Catalano, Tima Davidson, Liran Domachevsky
Department of Nuclear Medicine, Sheba Medical Center, Tel-Hashomer, 31 Emek Ha'ela Street, Ramat Gan 52621, Israel. Electronic address: ., Department of Nuclear Medicine, Sheba Medical Center, Tel-Hashomer, 31 Emek Ha'ela Street, Ramat Gan 52621, Israel; Faculty of Medicine, Tel Aviv University, 35 klachkin Street, Tel Aviv 69978, Israel., Faculty of Medicine, Tel Aviv University, 35 klachkin Street, Tel Aviv 69978, Israel; Genitourinary Oncology Unit, The Jusidman Oncology Hospital, Sheba Medical center, 31 Emek Ha'ela Street, Ramat Gan 52621, Israel., Faculty of Medicine, Tel Aviv University, 35 klachkin Street, Tel Aviv 69978, Israel; Department of Urology, Sheba Medical Center, Tel-Hashomer, 31 Emek Ha'ela Street, Ramat Gan 52621, Israel., Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.